Deflazacort (Deflazacort) Patent Expiration, LOE Window & CMS Spending
Deflazacort (Deflazacort) by Aurobindo Pharma: Multi-Source Generic Molecule, 12 AB generics, $21.7M 2024 CMS Part D & Medicaid spend, and $14,215 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Aurobindo Pharma |
| FDA Application & Pathway | Reconciled (ANDA) |
| Exclusivity / Cliff Horizon | Multi-Source Generic Molecule |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 12 |
| 2024 CMS Total Public Spend | $21.7M |
| 2024 Medicare Part D Spend | $1.3M |
| 2024 Medicaid Spend | $20.4M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($14,215 intro WAC) |